A phase Ib study to assess the safety of the human papillomavirus DNA vaccine (AMV002) in combination with durvalumab for HPV-associated oropharyngeal squamous cell carcinoma.

Saved in:
Bibliographic Details
Title: A phase Ib study to assess the safety of the human papillomavirus DNA vaccine (AMV002) in combination with durvalumab for HPV-associated oropharyngeal squamous cell carcinoma.
Authors: Ladwa R; Department of Cancer Services, Princess Alexandra Hospital, Brisbane, Australia.; Frazer Institute, Faculty of Medicine, The University of Queensland, Brisbane, Australia., Chandra J; Frazer Institute, Faculty of Medicine, The University of Queensland, Brisbane, Australia., Woo WP; Frazer Institute, Faculty of Medicine, The University of Queensland, Brisbane, Australia.; Jingang Medicine (Australia) Pty Ltd, Brisbane, Australia., Finlayson N; Jingang Medicine (Australia) Pty Ltd, Brisbane, Australia., Liu H; Department of Cancer Services, Princess Alexandra Hospital, Brisbane, Australia.; Frazer Institute, Faculty of Medicine, The University of Queensland, Brisbane, Australia., McGrath M; Department of Cancer Services, Princess Alexandra Hospital, Brisbane, Australia., See A; Department of Cancer Services, Princess Alexandra Hospital, Brisbane, Australia., Hughes BG; Frazer Institute, Faculty of Medicine, The University of Queensland, Brisbane, Australia.; Department of Cancer Services, Royal Brisbane Hospital, Brisbane, Australia., Cooper CL; Frazer Institute, Faculty of Medicine, The University of Queensland, Brisbane, Australia.; Pathology Queensland, Princess Alexandra Hospital, Brisbane, Australia., Jackson JE; Department of Cancer Services, Gold Coast University Hospital, Gold Coast, Australia., Dzienis M; Department of Cancer Services, Gold Coast University Hospital, Gold Coast, Australia., Xu Y; Frazer Institute, Faculty of Medicine, The University of Queensland, Brisbane, Australia.; Jingang Medicine (Australia) Pty Ltd, Brisbane, Australia., Panizza B; Frazer Institute, Faculty of Medicine, The University of Queensland, Brisbane, Australia.; ENT Department, Princess Alexandra Hospital, Brisbane, Australia., Frazer I; Frazer Institute, Faculty of Medicine, The University of Queensland, Brisbane, Australia.; Jingang Medicine (Australia) Pty Ltd, Brisbane, Australia., Porceddu SV; Department of Cancer Services, Princess Alexandra Hospital, Brisbane, Australia.; Frazer Institute, Faculty of Medicine, The University of Queensland, Brisbane, Australia.
Source: Frontiers in oncology [Front Oncol] 2024 Jul 05; Vol. 14, pp. 1419258. Date of Electronic Publication: 2024 Jul 05 (Print Publication: 2024).
Publication Type: Journal Article
Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2234-943X
DOI:10.3389/fonc.2024.1419258